Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Eli Lilly

Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their emergency use authorization has been rescinded by the U.S. Food And Drug Administration. What Happened: The regulator said in a statement, “data show these treatments are highly unlikely to be active against the omicron variant, which is circulating at a very high frequency throughout the United States, these treatments are not authorized for use in any U.S. states, territories, and jurisdictions at this time.

FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why

Monoclonal antibody treatments by Regeneron and Eli Lilly proved ineffective against the omicron variant, the FDA said.

FDA Rescinds Authorization For Covid Antibody Treatments By Regeneron, Eli Lilly

Regeneron (REGN) is expected to maintain momentum on the back of a solid and diverse portfolio. The promising pipeline also sets the stage for further growth.

Regeneron (REGN) Rides on Solid Product Portfolio: Should You Buy?

Sanofi

Regeneron (REGN) sBLA seeking label expansion of Libtayo in combination with chemotherapy as first-line treatment in advanced lung cancer accepted by the FDA.

Regeneron (REGN)/Sanofi's Libtayo sBLA Accepted by the FDA

TARRYTOWN, N.Y. and WASHINGTON, Jan. 20, 2022 /PRNewswire/ --  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today named 40 finalists in this year's Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors.

Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent Search

BioNTech SE

Vertex Pharmaceuticals

Regeneron (REGN), Vertex Pharmaceuticals (VRTX) and BioNTech (BNTX) are three large biotech stocks that are worth betting on in the current scenario.

Will 2022 Be a Better Year for Biotech Than 2021? 3 Big Picks

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced data from the second Phase 3 trial of Dupixent (dupilumab) in adults with uncontrolled prurigo nodularis, a chronic type 2 inflammatory skin disease.  The trial met its primary and key secondary endpoints, showing it significantly reduced itch and skin lesions compared to placebo at 24 weeks.

Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease

Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC

TARRYTOWN, N.Y., Jan. 19, 2022 /PRNewswire/ --  Regulatory filing recently submitted in the European Union Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for PD-1 inhibitor Libtayo® (cemiplimab-rwlc) in combination with chemotherapy as first-line treatment in advanced non-small cell lung cancer (NSCLC).

FDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLC

Second positive Phase 3 Dupixent ® (dupilumab) trial confirms significant improvement s for patients with prurigo nodularis

Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis

Bunge Global SA

CommScope Hld

Hologic

Microchip Technology

CommScope (COMM), Microchip (MCHP), Regeneron (REGN), Bunge (BG) and Hologic (HOLX) are some of the stocks with high ROE to profit as Q4 earnings witness shaky start to the season.

5 ROE Stocks to Buy as Q4 Earnings Witness Shaky Start

Moderna

Both companies are involved in the fight against COVID-19.

2 Top Biotech Stocks to Buy and Hold for 10 Years

TARRYTOWN, N.Y., Jan. 13, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2021 financial and operating results on Friday, February 4, 2022, before the U.S. financial markets open.

Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast on

Regeneron Pharmaceuticals, Inc. (REGN) CEO Len Schleifer Presents at 40th Annual JPMorgan Virtual Healthcare Conference (Transcript)

Ultragenyx Pharmaceutical

Regeneron (REGN) teams up with Ultragenyx Pharmaceutical to commercialize and distribute Evkeeza (evinacumab) outside the United States.

Regeneron (REGN) Collaborates With Ultragenyx for Evkeeza

The stock price of ​Regeneron has seen a 6% fall over the last twenty-one trading days, while it is down 7% over the last week. The volatility in REGN stock is being driven by the developments for REGEN-COV, its Covid-19 antibody cocktail.

Will Regeneron Stock Rebound After Its Recent 6% Fall?

Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United States

Regeneron (REGN) closed at $598.44 in the latest trading session, marking a +0.56% move from the prior day.

Regeneron (REGN) Gains As Market Dips: What You Should Know

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was a notable beneficiary of the global pandemic that resulted in a 30% increase in its stock price last year. But BofA Securities warns 2022 will be a very different story.

This biotech stock is a buy despite bearish view from BofA Securities

Pfizer

An analyst at BofA Securities on Wednesday shared a pair trade idea in the large-cap pharma space. The Biopharma Analyst: Geoff Meacham upgraded Pfizer, Inc. (NYSE:PFE) shares from Neutral to Buy and increased the price target from $59 to $70.

Why This Pfizer, Regeneron Analyst Has Contrasting Recommendations For The COVID Stock Plays

Align Technology

Intellia Therapeutics

A key clinical trial, an enormous market opportunity, and breakthrough biotechnology could drive returns for shareholders this year.

3 Healthcare Stocks That Could Rocket Higher in 2022

Avid Bioservices

Gilead Sciences

3 Biopharma Stocks Displaying Relative Strength Heading Into 2022

Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength

The latest variant of the coronavirus pandemic, Omicron, is wreaking havoc in the global stock markets. However, as some companies struggle with the adverse economic effects of the pandemic, a few could gain significantly from the products they have created to mitigate the pandemic.

Best covid stocks to buy now

Regulators say it is "unlikely" the drugs will have an effect against the new variant, pending new data.

U.S. Halts Distribution of Regeneron and Eli Lilly Covid Antibody Drugs

Regeneron easily beat the revenue and EPS expectation for 3Q 2021. Rapid revenue growth will continue into the foreseeable future, thanks to strong EYLEA, Dupixent, and Covid-treatment performance.

News for Regeneron Pharmaceuticals Stock (REGN)